JP2000506723A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2000506723A5 JP2000506723A5 JP1997529893A JP52989397A JP2000506723A5 JP 2000506723 A5 JP2000506723 A5 JP 2000506723A5 JP 1997529893 A JP1997529893 A JP 1997529893A JP 52989397 A JP52989397 A JP 52989397A JP 2000506723 A5 JP2000506723 A5 JP 2000506723A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9603507.6A GB9603507D0 (en) | 1996-02-20 | 1996-02-20 | Antibody variants |
| GB9603507.6 | 1996-02-20 | ||
| PCT/GB1997/000472 WO1997031024A1 (en) | 1996-02-20 | 1997-02-20 | Antibody variants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2000506723A JP2000506723A (ja) | 2000-06-06 |
| JP2000506723A5 true JP2000506723A5 (cg-RX-API-DMAC7.html) | 2004-11-25 |
| JP4574750B2 JP4574750B2 (ja) | 2010-11-04 |
Family
ID=10789047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52989397A Expired - Lifetime JP4574750B2 (ja) | 1996-02-20 | 1997-02-20 | 抗体変異物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20020048578A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP0970127B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4574750B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE373016T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU723366B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2246715C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69738138T2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2294793T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB9603507D0 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ331299A (cg-RX-API-DMAC7.html) |
| WO (1) | WO1997031024A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1143006T3 (da) * | 1995-08-18 | 2008-07-14 | Morphosys Ip Gmbh | Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| JP2002530081A (ja) | 1998-11-18 | 2002-09-17 | ジェネンテック・インコーポレーテッド | 親抗体より高度な結合親和性を持つ抗体変異体 |
| JP4334866B2 (ja) * | 2000-10-09 | 2009-09-30 | アイシス イノヴェイション リミテッド | 治療用抗体 |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| US20040109855A1 (en) * | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| KR20060002896A (ko) * | 2003-03-31 | 2006-01-09 | 기린 비루 가부시키가이샤 | 항 ｃｄ52 항체에 의한 조절성 ｔ 세포 분화 유도ㆍ증식방법 및 그를 위한 의약 조성물 |
| AU2005246073B2 (en) * | 2004-05-19 | 2010-10-28 | Adaptimmune Limited | Method of improving T cell receptors |
| CA2601400A1 (en) * | 2005-03-19 | 2006-09-28 | Medical Research Council | Improvements in or relating to treatment and prevention of viral infections |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US20100197896A1 (en) * | 2007-05-16 | 2010-08-05 | Leung Shui-On | Functional humanization of complementarity determining regions (cdrs) |
| EP2190861A4 (en) | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| BRPI1006141B8 (pt) | 2009-01-12 | 2021-05-25 | Cytomx Therapeutics Llc | composições de anticorpo modificado, métodos para preparar e usar as mesmas |
| CN102481341B (zh) | 2009-02-23 | 2017-05-17 | 希托马克斯医疗有限公司 | 蛋白原及其使用方法 |
| KR20140102764A (ko) | 2009-05-13 | 2014-08-22 | 겐자임 코포레이션 | 항-인간 ｃｄ52 면역글루불린 |
| AU2010252939B2 (en) | 2009-05-29 | 2014-06-26 | Morphosys Ag | A collection and methods for its use |
| US8367586B2 (en) | 2010-11-19 | 2013-02-05 | Morphosys Ag | Collection and methods for its use |
| GB201109238D0 (en) * | 2011-06-01 | 2011-07-13 | Antitope Ltd | Antibodies |
| WO2013152011A1 (en) * | 2012-04-02 | 2013-10-10 | Ab Biosciences, Inc. | Novel human control antibodies and uses therefor |
| AU2013251310B2 (en) | 2012-04-27 | 2018-02-15 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| KR20150139955A (ko) | 2013-04-09 | 2015-12-14 | 보스톤 바이오메디칼, 인크. | 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온 |
| US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
| US20160120158A1 (en) * | 2014-11-03 | 2016-05-05 | The Johns Hopkins University | Compositions and methods for the study and treatment of acute kidney injury |
| TW201717935A (zh) | 2015-06-03 | 2017-06-01 | 波士頓生醫公司 | 用於治療癌症的組成物和方法 |
| US11299469B2 (en) | 2016-11-29 | 2022-04-12 | Sumitomo Dainippon Pharma Oncology, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| CA3062656A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
| CA3137587A1 (en) | 2019-04-30 | 2020-11-05 | Institute For Cancer Research D/B/A/ The Research Institute Of Fox Chase Cancer Center | Compositions and methods for modulation of antibody activity |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0328404B1 (en) * | 1988-02-12 | 1993-09-29 | Btg International Limited | Modified antibodies |
| US5846534A (en) | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
| US5858725A (en) | 1990-10-10 | 1999-01-12 | Glaxo Wellcome Inc. | Preparation of chimaeric antibodies using the recombinant PCR strategy |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DK0610447T3 (da) * | 1991-10-15 | 1999-08-23 | Btg Int Ltd | CDw52-specifikt antistof til behandling af T-cellemedieret inflammation af leddene |
| GB9125768D0 (en) * | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
-
1996
- 1996-02-20 GB GBGB9603507.6A patent/GB9603507D0/en active Pending
-
1997
- 1997-02-20 WO PCT/GB1997/000472 patent/WO1997031024A1/en not_active Ceased
- 1997-02-20 ES ES97905226T patent/ES2294793T3/es not_active Expired - Lifetime
- 1997-02-20 EP EP97905226A patent/EP0970127B1/en not_active Expired - Lifetime
- 1997-02-20 NZ NZ331299A patent/NZ331299A/xx not_active IP Right Cessation
- 1997-02-20 CA CA002246715A patent/CA2246715C/en not_active Expired - Fee Related
- 1997-02-20 AU AU18851/97A patent/AU723366B2/en not_active Ceased
- 1997-02-20 US US09/125,460 patent/US20020048578A1/en not_active Abandoned
- 1997-02-20 JP JP52989397A patent/JP4574750B2/ja not_active Expired - Lifetime
- 1997-02-20 DE DE69738138T patent/DE69738138T2/de not_active Expired - Lifetime
- 1997-02-20 AT AT97905226T patent/ATE373016T1/de not_active IP Right Cessation
-
2005
- 2005-07-14 US US11/180,631 patent/US8440190B2/en not_active Expired - Fee Related